Figure 1.

Patients with ovarian tumors harboring an impaired FA pathway show a better prognosis than those patients with tumors carrying an intact pathway. Seventeen FA genes were input into c-Bioportal when choosing TCGA data set containing 316 tumor samples.⁶ The output shows that 40% of 316 quarried samples carry a mutated FA pathway, and the mutated status (red lines) is significantly associated with the survival as well as the period of disease free (in months) via Kaplan-Meier Estimate. Those patients were all treated with Cisplatin.⁶